
Keros Therapeutics Inc (KROS) receives a Neutral rating from BofA Securities
Keros Therapeutics Inc’s recently made public that its Affiliate Rovaldi Christopher acquired Company’s shares for reported $1.34 million on Sep
Keros Therapeutics Inc’s recently made public that its Affiliate Rovaldi Christopher acquired Company’s shares for reported $1.34 million on Sep
Keros Therapeutics Inc’s filing revealed that its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46 million
In a filing, Keros Therapeutics Inc revealed its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46
In a filing, Keros Therapeutics Inc revealed its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46
In a filing, Keros Therapeutics Inc revealed its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46
Keros Therapeutics Inc’s recent filing unveils that its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Keros Therapeutics Inc’s filing revealed that its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46 million
Keros Therapeutics Inc’s filing revealed that its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46 million